Losartan and sunitinib for advanced osteosarcoma
Part of Cancer clinical trials.
This trial tests a combination of two drugs, losartan and sunitinib, in people with osteosarcoma that has come back or spread after prior treatment. The study aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 10 years of age or older.
- You must have osteosarcoma that has returned or spread after at least one prior treatment.
- Your osteosarcoma must not be the surface or periosteal type.
- You must not have active brain metastases, unless they were treated more than 3 months ago and are stable.
- Your bone marrow, kidney, and liver function must be adequate as per protocol.
- You must be able to take medications by mouth or through a feeding tube.
- You must not have had major surgery within the last 14 days.
- You must not have an uncontrolled bleeding disorder or active bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pill called sulfatinib for young people with bone cancer (osteosarcoma) that has come back or not responded to standard treatments. Sulfatinib works by cutting off the blood supply that tumors need to grow, and the goal is to see if it can control the cancer.
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
This trial studies a new combination of two drugs, domatinostat and sirolimus, for people with sarcoma or osteosarcoma that hasn't improved after standard treatments. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests a new drug, HS-20093, combined with other treatments for people with advanced bone or soft tissue sarcoma. The goal is to see if these combinations can shrink tumors or slow their growth.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial tests a new drug called vactosertib for people with a type of bone cancer called osteosarcoma that has come back or hasn't responded to other treatments. The goal is to see if the drug can help shrink or slow the cancer and to check its safety.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.